miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1

Anti-microRNA-222 (Anti-miR-222) and -181B Suppress Growth of Tamoxifen-resistant Xenografts in Mouse by Targeting TIMP3 Protein and Modulating Mitogenic Signal

(2011) Yuanzhi Lu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells

(2011) Chun-Ju Yang et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

StatBite Ovarian Cancer, Five-Year Stage-Specific Relative Survival Rates (2004-2008)

(2011)   JNCI-Journal of the National Cancer Institute

miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ

(2011) C Quintavalle et al.   ONCOGENE

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma

(2010) Chun-Zhi Zhang et al.   Molecular Cancer

Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival

(2009) Thomas Greither et al.   INTERNATIONAL JOURNAL OF CANCER

Cytoplasmic p27 Expression is an Independent Prognostic Factor in Ovarian Cancer

(2009) Timothy J. Duncan et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1

(2008) Tyler E. Miller et al.   JOURNAL OF BIOLOGICAL CHEMISTRY